试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-04-04
Sapanisertib Before and After Surgery in Treating Patients With Recurrent Glioblastoma
编号:NCT02133183登记状态:提前终止企业 / 申办者:National Cancer Institute (NCI)
药物 / 成分:Laboratory Biomarker Analysis、Pharmacological Study、Sapanisertib、Therapeutic Conventional Surgery
登记的停止原因(原文):Other - Lapse in funding
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-04-04
A Biomarker Study in Advanced Mucosal or Acral Lentiginous Melanoma Receiving Nivolumab in Combination With Ipilimumab
编号:NCT02978443登记状态:提前终止企业 / 申办者:Georgetown University
药物 / 成分:Nivolumab、Ipilimumab
登记的停止原因(原文):Lack of Enrollment
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-04-04
AGEN1884 Plus AGEN2034 Combined With Cisplatin-Gemcitabine for Muscle-Invasive Bladder Cancer
编号:NCT04430036登记状态:提前终止企业 / 申办者:The University of Texas Health Science Center at San Antonio
药物 / 成分:AGEN1884、AGEN2034、Cisplatin、Gemcitabine
登记的停止原因(原文):PI left the institution
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-04-04
Tofacitinib For Treatment Of Chronic Pouchitis
编号:NCT04580277登记状态:提前终止企业 / 申办者:Cedars-Sinai Medical Center
药物 / 成分:Tofacitinib 10 mg
登记的停止原因(原文):low recruitment
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-04-04
Varenicline For Nicotine Vaping Cessation In Non Smoker Vaper Adolescents
编号:NCT04602494登记状态:提前终止企业 / 申办者:Massachusetts General Hospital
药物 / 成分:Varenicline、Placebo
登记的停止原因(原文):The pilot study used apo-varenicline under temp FDA authorization. When varenicline was available an IND exemption was granted to enroll children, IRB approved a trial of varenicline in participants ages 16-25 June 27, 2022, the pilot was terminated
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-04-04
Derazantinib Alone or in Combination With Paclitaxel, Ramucirumab or Atezolizumab in Gastric Adenocarcinoma
编号:NCT04604132登记状态:提前终止企业 / 申办者:Basilea Pharmaceutica
药物 / 成分:Derazantinib、Derazantinib-paclitaxel-ramucirumab combination、Derazantinib-paclitaxel-ramucirumab combination、Derazantinib
登记的停止原因(原文):Terminated prematurely for administrative reasons not related to patient safety.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-04-04
Tinzaparin Lead-In to Prevent the Post-Thrombotic Syndrome
编号:NCT04794569登记状态:提前终止企业 / 申办者:Sunnybrook Health Sciences Centre
药物 / 成分:tinzaparin、Rivaroxaban
登记的停止原因(原文):funding discontinued
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-04-04
Bempegaldesleukin (NKTR-214) With Radiation and Anti-PD-1 Immunotherapy for Head and Neck Squamous Cell Carcinoma
编号:NCT04936841登记状态:提前终止企业 / 申办者:University of Wisconsin, Madison
药物 / 成分:NKTR-214、anti-PD-1 therapy、Palliative Radiation
登记的停止原因(原文):study closed by the sponsor
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-04-03
Preventing Sickle Cell Kidney Disease
编号:NCT02373241登记状态:提前终止企业 / 申办者:University of Alabama at Birmingham
药物 / 成分:Losartan、Losartan
登记的停止原因(原文):Estimated GFR was determined not to be a reliable endpoint for this study. We identified significant variabilty in annual eGFR that it became inappropriate to randomize to a medication but use EGFR as the primary endpoint.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-04-03
A Pre-Surgical PK Study of IM and Intraductally Delivered Fulvestrant
编号:NCT02540330登记状态:提前终止企业 / 申办者:Atossa Therapeutics, Inc.
药物 / 成分:Fulvestrant
登记的停止原因(原文):Business decision (See Detailed Description)
查看官方原始记录 ↗